Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
FBR Capital Remains Bullish as Prima BioMed (PBMD) Announces Investigator-Sponsored Trial
July 12, 2016 1:47 PM EDTFBR Capital reiterated an Outperform rating and $6.00 price target on Prima Biomed (NASDAQ: PBMD) following the company's announced collaboration for an investigator-sponsored clinical trial.
Analyst Vernon Bernardino commented, "Earlier today, July 12, Prima BioMed (PBMD) announced a new collaboration for an investigatorsponsored clinical trial named INSIGHT to evaluate intra-tumoral injection of PBMDs immune-oncology therapy,... More



